ArticleJournal of clinical medicine2023
Tirbanibulin 1% Ointment Significantly Reduces the Actinic Keratosis Area and Severity Index in Patients with Actinic Keratosis: Results from a Real-World Study.
Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Clinical Clearance of Actinic Keratoses with Tirbanibulin 1% Ointment: Evidence from a Meta-Analysis.Life (Basel, Switzerland) · 2026Article
- Real-World Data on Characteristics and Management of Patients with Actinic Keratosis: A Cancer Center Experience.Medical sciences (Basel, Switzerland) · 2026Article
- Tirbanibulin 1% real-world use in 679 actinic keratoses patients during warm season (SUMM-AK study).Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Efficacy and Safety of Tirbanibulin 1% Ointment for Actinic Keratosis at 1-Year Follow-Up: A Real-Life Extension Study.Medicina (Kaunas, Lithuania) · 2026Article
- Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025Article
- The State of the Art in the Treatment of Actinic Keratosis and Field Cancerization: A Narrative Review.Journal of personalized medicine · 2025Review
- Tirbanibulin 1% Ointment for the Treatment of Hyperkeratotic Actinic Keratosis.The Journal of dermatology · 2025Article
- Real-World Efficacy of Tirbanibulin in Actinic Keratosis Treatment: Expert Consensus and Clinical Insights.Dermatology practical & conceptual · 2025Review
- Field Cancerization Treatment with Tirbanibulin 1% Ointment: Results in Real-World Practice.Acta dermato-venereologica · 2025Article
- Clinical and experimental aspects of tirbanibulin treatments.Archives of dermatological research · 2025Review
- Exploring Anti-Aging Effects of Topical Treatments for Actinic Keratosis.Medicina (Kaunas, Lithuania) · 2025Review
- The Skin-Lightening Power of Tirbanibulin 1% Ointment.Dermatology and therapy · 2025Article
- [Update in the diagnosis and treatment of actinic keratosis].Dermatologie (Heidelberg, Germany) · 2024Review
- Topical Pharmacological Treatment of Actinic Keratoses: Focus on Tirbanibulin 1% Ointment.Dermatology practical & conceptual · 2024Review
- Anti-aging Effects of Tirbanibulin 1% Ointment: A Real-Life Experience.Dermatology and therapy · 2024Article
- Cutaneous Squamous Cell Carcinoma: An Updated Review.Cancers · 2024Review
- Tirbanibulin 1% Ointment for Actinic Keratosis: Results from a Real-Life Study.Medicina (Kaunas, Lithuania) · 2024Article
- Preliminary Evidence of Efficacy, Safety, and Treatment Satisfaction with Tirbanibulin 1% Ointment: A Clinical Perspective on Actinic Keratoses.Pharmaceuticals (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundActinic keratosis (AK) is a cutaneous lesion resulting from the proliferation of atypical epidermal keratinocytes caused by long-term exposure to ultraviolet radiation. AK may progress to cutaneous squamous cell carcinoma (cSCC) and therefore is often treated with topical agents such as 5-fluorouracil, diclofenac, imiquimod, and photodynamic therapy. Tirbanibulin has been approved based on two phase III trials in the USA. However, real-world evidence for tirbanibulin is absent.
methodsThis was a single-centre study of adult patients with clinically typical, visible AK on the face or scalp treated with tirbanibulin 1% ointment. Treatment was administered as per label once daily for 5 consecutive days on the same lesions or field. Treatment outcomes were assessed 4 weeks after treatment, with additional optional assessments conducted at later time points. Efficacy was measured using the actinic keratosis area and severity index (AKASI) and digital dermoscopy.
resultsA total of 33 patients were treated of whom 30 were analysed. The median AKASI score was 5.6 (1.4-11) pre-treatment and 1.2 (0-7.4) post-treatment (
conclusionsTirbanibulin 1% ointment significantly and rapidly reduced the AKASI score in a real-world setting. The complete clearance rates were in line with those observed in the two pivotal trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.